Stock Research for AERI

AERI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AERI Stock Chart & Research Data

The AERI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AERI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AERI Due diligence Resources & Stock Charts

The AERI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AERI Detailed Price Forecast - CNN Money CNN View AERI Detailed Summary - Google Finance
Yahoo View AERI Detailed Summary - Yahoo! Finance Zacks View AERI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AERI Trends & Analysis - Trade-Ideas Barrons View AERI Major Holders - Barrons
NASDAQ View AERI Call Transcripts - NASDAQ Seeking View AERI Breaking News & Analysis - Seeking Alpha
Spotlight View AERI Annual Report - CompanySpotlight.com OTC Report View AERI OTC Short Report - OTCShortReport.com
TradeKing View AERI Fundamentals - TradeKing Charts View AERI SEC Filings - Bar Chart
WSJ View Historical Prices for AERI - The WSJ Morningstar View Performance/Total Return for AERI - Morningstar
MarketWatch View the Analyst Estimates for AERI - MarketWatch CNBC View the Earnings History for AERI - CNBC
StockMarketWatch View the AERI Earnings - StockMarketWatch MacroAxis View AERI Buy or Sell Recommendations - MacroAxis
Bullish View the AERI Bullish Patterns - American Bulls Short Pains View AERI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AERI Stock Mentions - StockTwits PennyStocks View AERI Stock Mentions - PennyStockTweets
Twitter View AERI Stock Mentions - Twitter Invest Hub View AERI Investment Forum News - Investor Hub
Yahoo View AERI Stock Mentions - Yahoo! Message Board Seeking Alpha View AERI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AERI - SECform4.com Insider Cow View Insider Transactions for AERI - Insider Cow
CNBC View AERI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AERI - OTC Markets
Yahoo View Insider Transactions for AERI - Yahoo! Finance NASDAQ View Institutional Holdings for AERI - NASDAQ


Stock Charts

FinViz View AERI Stock Insight & Charts - FinViz.com StockCharts View AERI Investment Charts - StockCharts.com
BarChart View AERI Stock Overview & Charts - BarChart Trading View View AERI User Generated Charts - Trading View




Latest Financial News for AERI


See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
Posted on Saturday September 15, 2018

Short interest is moderate for AERI with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.


Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
Posted on Thursday September 13, 2018

Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Ophthalmology Futures European Forum held prior to the 36th Congress ...


Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors
Posted on Wednesday September 12, 2018

Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that David W. Gryska has been appointed to the Company’s Board of Directors and will also be a member of the Audit Committee of the Board. Mr. Gryska recently announced his planned retirement at the end of 2018 as the Chief Financial Officer and Executive Vice President of Incyte Corp., and is currently on the boards of Seattle Genetics, Inc. and PDL BioPharma, Inc. Previously, he held the position of President, CEO, COO and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice President at Celgene Corp., and Chief Financial Officer and Senior Vice President at Scios, Inc. Mr. Gryska has spent over 20 years as a senior executive at life science and biotechnology companies with extensive experience relating to financings, acquisitions, global expansion and strategic transactions.


Today's Research Reports on Trending Tickers: Momenta Pharmaceuticals and Aerie Pharmaceuticals
Posted on Wednesday September 12, 2018

The Dow Jones Industrial Average climbed 0.44 percent to close at 25,971.06, while the S&P 500 Index increased 0.37 percent to close at 2,887.89. The Nasdaq Composite Index gained 0.61 percent to close at 7,972.47.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.